ondansetron has been researched along with Carcinoid Tumor in 2 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Carcinoid Tumor: A usually small, slow-growing neoplasm composed of islands of rounded, oxyphilic, or spindle-shaped cells of medium size, with moderately small vesicular nuclei, and covered by intact mucosa with a yellow cut surface. The tumor can occur anywhere in the gastrointestinal tract (and in the lungs and other sites); approximately 90% arise in the appendix. It is now established that these tumors are of neuroendocrine origin and derive from a primitive stem cell. (From Stedman, 25th ed & Holland et al., Cancer Medicine, 3d ed, p1182)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ishizuka, J | 1 |
Hsieh, AC | 1 |
Townsend, CM | 1 |
Thompson, JC | 1 |
Jacobsen, MB | 1 |
2 other studies available for ondansetron and Carcinoid Tumor
Article | Year |
---|---|
Effect of 5-HT3 receptor antagonist (ondansetron) on functioning human pancreatic carcinoid cells.
Topics: Calcium; Carcinoid Tumor; Cell Division; Cyclic AMP; Dose-Response Relationship, Drug; Humans; Hydro | 1993 |
Ondansetron in carcinoid syndrome.
Topics: Aged; Carcinoid Tumor; Humans; Imidazoles; Male; Ondansetron; Pancreatic Neoplasms; Serotonin Antago | 1992 |